Novo Nordisk investing $2.6 billion in expanding Danish facility

Danish diabetes care giant Novo Nordisk (NOV: N) today announced plans to invest more than 17 billion Danish kroner ($2.58 billion) in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark

The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products. The new facilities will be automated and include state-of-the-art production technologies.

“This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, executive vice president, product supply, quality and IT, Novo Nordisk. ​